Immatics N.V. (IMTX) vs Vor Biopharma (VOR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Vor Biopharma (VOR) has outperformed Immatics N.V. (IMTX) over the past year, gaining 157.6% versus a loss of 43.4%. Over five years, IMTX leads with a -48.6% price change compared with -92.0% for VOR. Vor Biopharma is the larger company by market cap ($1.18 billion vs $878.6 million), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMTX | VOR |
|---|---|---|
| Share price | $5.77 | $19.19 |
| Market cap | $878.58M | $1.18B |
| 1-day change | -3.03% | +3.62% |
| YTD return | -45.05% | +46.71% |
| 1-year return | -43.43% | +157.58% |
| 5-year return | -48.57% | -92.00% |
| P/E ratio (TTM) | — | 0.06 |
| EPS (TTM) | $-1.95 | $300.56 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | — | $-695.98M |
| 52-week high | $12.41 | $26.00 |
| 52-week low | $5.72 | $7.21 |
| Distance from 52-week high | -53.51% | -26.19% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +176.78% | +103.23% |
| Average volume | 962.74K | 945.67K |
| Shares outstanding | 152.27M | 61.43M |
| Employees | 721 | 76 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VOR has outperformed IMTX by 201.0 percentage points over the past year.
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 721 employees
About Vor Biopharma
VOR stock →Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 76 employees
IMTX vs VOR FAQ
Which is bigger, Immatics N.V. or Vor Biopharma?
Vor Biopharma (VOR) is larger, with a market capitalization of $1.18B compared with $878.58M for Immatics N.V. (IMTX).
Which stock has performed better over the past year, IMTX or VOR?
VOR returned +157.58% over the past 12 months, compared with -43.43% for IMTX (price return, excluding dividends). Past performance does not predict future results.
Are Immatics N.V. and Vor Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.